SCHEMBL4270048

SCHEMBL4270048

Nc1ccc(OCCN2CCOCC2)c(Cl)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.63
ALDH1A1 P00352 2/20 0.62
MAPT P10636 2/20 0.62
HTT P42858 1/20 0.62
KDM4E B2RXH2 1/20 0.57
HSP90AA1 P07900 1/20 0.55
HSP90AB1 P08238 1/20 0.55
KMO O15229 2/20 0.54
NPC1 O15118 2/20 0.53
POLB P06746 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
MEN1 O00255 1/20 0.52
TP53 P04637 1/20 0.52
HPGD P15428 1/20 0.52
RAB9A P51151 1/20 0.52
KMT2A Q03164 1/20 0.52
HTR2C P28335 1/20 0.52
HTR2B P41595 1/20 0.52
LTA4H P09960 1/20 0.51
EPHX2 P34913 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14937929 0.89 TSHR (0.75) TSHRALDH1A1MAPTHTTKDM4E
SCHEMBL1024536 0.87 TSHR (0.61) TSHRALDH1A1KDM4ESMN1; SMN2HTR2C
SCHEMBL11752723 0.86 TSHR (0.55) TSHRALDH1A1MAPTHTTKDM4E
SCHEMBL14233388 0.86 TSHR (0.64) TSHRALDH1A1KDM4EPOLBSMN1; SMN2
Hydrochloric Acid SCHEMBL1641395 0.86 LTA4H (0.60) TSHRALDH1A1KDM4ESMN1; SMN2HTR2C
SCHEMBL14578278 0.84 LTA4H (0.70) TSHRALDH1A1MAPTHTTKDM4E
SCHEMBL4266650 0.84 POLB (0.54) TSHRALDH1A1MAPTHTTKDM4E
SCHEMBL17610020 0.83 TSHR (0.59) TSHRALDH1A1MAPTHTTKDM4E
SCHEMBL30962888 0.83 POLB (0.59) TSHRALDH1A1KDM4ENPC1POLB
SCHEMBL3863038 0.83 POLB (0.57) TSHRALDH1A1MAPTHTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605176-B2 β-ketoamide compounds with MCH antagonistic activity BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-10-20 US disclosed
EP-1730130-A1 BETA-KETOAMIDE COMPOUNDS HAVING AN MCH-ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING SAID COMPOUNDS Boehringer Ingelheim International GmbH (DE) 2006-12-13 EP disclosed
US-20050245500-A1 Beta-ketoamide compounds with MCH antagonistic activity BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-11-03 US disclosed
WO-2005085221-A1 BETA-KETOAMIDE COMPOUNDS HAVING AN MCH-ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING SAID COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-09-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245500-A1 Beta-ketoamide compounds with MCH antagonistic activity MCHR2, MCHR1, NPY1R TSHR 117/4885ALDH1A1 3664/4885MAPT 4030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.